References in periodicals archive ?
The most frequent all causality Grade 3-4 adverse reactions (>=5%) in patients treated with Cabometyx were hypertension, diarrhea, hyponatremia, hypophosphatemia, palmar-plantar erythrodysesthesia, fatigue, increased ALT, decreased appetite, stomatitis, pain, hypotension, and syncope.
This side effect is known variously as hand-foot syndrome, palmar-plantar erythrodysesthesia (PPE) or hand-to-foot syndrome.
In terms of extra-myelotoxicity other than cardiotoxicity, the occurrence of Palmar-Plantar Erythrodysesthesia (commonly known as a hand-foot syndrome) is similar in both liposomal and nonliposomal formulations of doxorubicin.
The most common side effects of Lenvima were high blood pressure (hypertension), fatigue, diarrhea, joint and muscle pain (arthralgia/myalgia), decreased appetite, decreased weight, nausea, inflammation of the lining of the mouth (stomatitis), headache, vomiting, excess protein in the urine (proteinuria), swelling and pain in the palms, hands and/or the soles of the feet (palmar-plantar erythrodysesthesia syndrome), abdominal pain and changes in voice volume or quality (dysphonia).
The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.
3) TEC includes Burgdorf's Reaction, erythrodysesthesia, acral erythema, toxic acral erythema, eccrine squamous syringometaplasia, epidermal dysmaturation, epidermal dystrophy, hand-foot syndrome, palmar-plantar erythema, palmarplantar dysesthesia, and neutrophilic eccrine hidradenitis.
Hand-foot syndrome (HFS) also called hand- foot skin reaction palmar-plantar erythrodysesthesia acral erythema Burgdorf reaction is a dose limiting cutaneous toxicity of many chemotherapeutic agents.
2] In cases of May cause palmar-plantar myelosuppression erythrodysesthesia, (especially of hematologic toxicity granulocytic series) and stomatitis, the dose can be reduced or delayed Doxorubicin Bleomycin sulfate hydrochloride Dose schedule 10-20 mg/[m.
20 April 2011 - Spanish biopharmaceutical company Advancell has announced the initiation of a clinical Phase IIb study of its treatment ATH008 for palmar-plantar erythrodysesthesia syndrome, or hand-foot syndrome, a painful side effect of chemotherapy.